Israel · Delayed Price · Currency is ILS · Price in ILA Together Pharma Statistics
Total Valuation
Together Pharma has a market cap or net worth of ILS 36.79 million. The enterprise value is 97.01 million.
| Market Cap | 36.79M |
| Enterprise Value | 97.01M |
Important Dates
The next estimated earnings date is Friday, November 27, 2026.
| Earnings Date | Nov 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Together Pharma has 17.35 million shares outstanding. The number of shares has increased by 23.93% in one year.
| Current Share Class | 17.35M |
| Shares Outstanding | 17.35M |
| Shares Change (YoY) | +23.93% |
| Shares Change (QoQ) | +21.96% |
| Owned by Insiders (%) | 75.15% |
| Owned by Institutions (%) | n/a |
| Float | 4.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.37 |
| PB Ratio | 0.76 |
| P/TBV Ratio | 1.54 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.97 |
| EV / EBITDA | 5.34 |
| EV / EBIT | 9.35 |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 1.30.
| Current Ratio | 1.26 |
| Quick Ratio | 0.43 |
| Debt / Equity | 1.30 |
| Debt / EBITDA | 3.49 |
| Debt / FCF | -6.80 |
| Interest Coverage | 1.48 |
Financial Efficiency
Return on equity (ROE) is -2.08% and return on invested capital (ROIC) is 9.74%.
| Return on Equity (ROE) | -2.08% |
| Return on Assets (ROA) | 4.22% |
| Return on Invested Capital (ROIC) | 9.74% |
| Return on Capital Employed (ROCE) | 13.61% |
| Weighted Average Cost of Capital (WACC) | 7.46% |
| Revenue Per Employee | 475,890 |
| Profits Per Employee | -2,429 |
| Employee Count | 210 |
| Asset Turnover | 0.65 |
| Inventory Turnover | 1.21 |
Taxes
In the past 12 months, Together Pharma has paid 744,000 in taxes.
| Income Tax | 744,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -44.20% in the last 52 weeks. The beta is 0.18, so Together Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.18 |
| 52-Week Price Change | -44.20% |
| 50-Day Moving Average | 226.08 |
| 200-Day Moving Average | 290.17 |
| Relative Strength Index (RSI) | 42.22 |
| Average Volume (20 Days) | 12,200 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Together Pharma had revenue of ILS 99.94 million and -510,000 in losses. Loss per share was -0.03.
| Revenue | 99.94M |
| Gross Profit | 27.41M |
| Operating Income | 10.38M |
| Pretax Income | -276,000 |
| Net Income | -510,000 |
| EBITDA | 16.66M |
| EBIT | 10.38M |
| Loss Per Share | -0.03 |
Balance Sheet
The company has 5.45 million in cash and 63.36 million in debt, with a net cash position of -57.90 million or -3.34 per share.
| Cash & Cash Equivalents | 5.45M |
| Total Debt | 63.36M |
| Net Cash | -57.90M |
| Net Cash Per Share | -3.34 |
| Equity (Book Value) | 48.66M |
| Book Value Per Share | 2.67 |
| Working Capital | 20.44M |
Cash Flow
In the last 12 months, operating cash flow was -7.67 million and capital expenditures -1.65 million, giving a free cash flow of -9.31 million.
| Operating Cash Flow | -7.67M |
| Capital Expenditures | -1.65M |
| Depreciation & Amortization | 6.28M |
| Net Borrowing | 5.15M |
| Free Cash Flow | -9.31M |
| FCF Per Share | -0.54 |
Margins
Gross margin is 27.43%, with operating and profit margins of 10.38% and -0.51%.
| Gross Margin | 27.43% |
| Operating Margin | 10.38% |
| Pretax Margin | -0.28% |
| Profit Margin | -0.51% |
| EBITDA Margin | 16.67% |
| EBIT Margin | 10.38% |
| FCF Margin | n/a |
Dividends & Yields
Together Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -23.93% |
| Shareholder Yield | -23.93% |
| Earnings Yield | -1.39% |
| FCF Yield | -25.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 13, 2023. It was a reverse split with a ratio of 0.1.
| Last Split Date | Aug 13, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Together Pharma has an Altman Z-Score of -0.57 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.57 |
| Piotroski F-Score | 3 |